Clinical testing for molecular targets for personalized treatment in lung cancer.

doi:10.1111/j.1440-1843.2012.02261.x

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Back to search

Article

Clinical testing for molecular targets for personalized treatment in lung cancer.

Respirology (Carlton, Vic.) - 1 Feb 2013

Lam David C L

Abstract excerpt

Lung cancer is the leading cause of cancer mortality worldwide. Over the past decades, the management of advanced stage lung cancer has been revolutionized from very limited options of systemic chemotherapy with limited efficacy to the present stage of testing for biomarkers (epidermal growth factor receptor (EGFR), gene mutations) to guide therapeutic decision and to improve efficacy of treatment. Relevant...

Topics

Anaplastic Lymphoma Kinase
Biomarkers
ErbB Receptors
Humans
Lung Neoplasms
Molecular Targeted Therapy
Mutation
Precision Medicine
Proto-Oncogene Proteins
Proto-Oncogene Proteins p21(ras)
Receptor Protein-Tyrosine Kinases
ras Proteins

Source

Open in PubMed

Identifiers

PMID: 22957484
DOI: 10.1111/j.1440-1843.2012.02261.x

Genes

EGFR
ALK
KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 30 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics